

CENTRAL FAX CENTER

JUL 19 2005

Merchant & Gould

An Intellectual Property Law Firm

1101 30th Street NW
Suite 500
Washington, D.C. 20007
TEL 202.625.8380
FAX 202.625.8381
www.merchant-
gould.com

A Professional Corporation

Fax Transmission | July 19, 2005

TO: Commissioner for Patents
Attn: Cybil Delacroix-Muirheid
P.O. Box 1450
Alexandria, VA 22313-1450

FROM: Ronald A. Daignault

OUR REF: 14217.1USC1
TELEPHONE: 202.625.8384

Total pages, including cover letter: **8**PTO FAX NUMBER 1-703-872-9306

If you do NOT receive all of the pages, please telephone us at 202.625.8380, or fax us at 202.625.8381.

Title of Document Transmitted:

Amendment

Applicant: Lautt
Serial No.: 10/761,596
Filed: January 21, 2004
Group Art Unit: 1614
Our Ref. No.: 14217.1USC1
Confirmation No. 4255

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
Name: Ronald A. Daignault
Reg. No.: 25,968

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.


Signature

7/19/05
Date

GEN031.DOT

RECEIVED
CENTRAL FAX CENTER

JUL 19 2005

**RESPONSE UNDER 37 C.F.R. 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1614**

S/N 10/761,596

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lautt	Examiner:	Delacroix-Muirheid
Serial No.:	10/761,596	Group Art Unit:	1614
Filed:	January 21, 2004	Docket No.:	14217.1USC1
Title:	METHOD FOR TREATING INSULIN RESISTANCE THROUGH HEPATIC NITRIC OXIDE		

AMENDMENT UNDER 37 C.F.R. § 1.116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Final Office Action of May 20, 2005, Applicants timely submit the following Amendment. Entry of this Amendment and reconsideration of the claims is respectfully requested because it is submitted to advance the case to issue or in better form for appeal. The amendment does not raise new issues nor contain new matter.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.